NEW YORK and CAMBRIDGE, Mass., Sept.
21, 2020 /PRNewswire/ -- TriNetX (www.trinetx.com), the
leading global health research network optimizing clinical research
to bring new therapies to market faster, today announced global
investment firm The Carlyle Group (NASDAQ: CG) has made a strategic
growth investment and will acquire a majority stake in the Company.
Terms of the transaction were not disclosed.
Since its founding in 2013, TriNetX has built the largest global
network of research hospitals and academic institutions, top
biotech and pharmaceutical companies, contract research
organizations (CROs) and other specialty data partners. TriNetX is
powered by an impressive network of 170 healthcare organizations in
30 countries and used by more than 40 life sciences organizations
including 15 of the world's top 20 pharmaceutical companies.
"Our goal is to be on the desktop of every healthcare researcher
in the world," said Gadi Lachman,
CEO of TriNetX. "To accomplish this we need to continue to
develop solutions to support clinical research at our healthcare
organizations and bring more global data and technologies such as
AI, machine learning and analytics to researchers so that they can
ask more questions and generate more real-world evidence. Carlyle's
investment accelerates our growth plans and will shorten the time
it takes to turn our vision into reality."
TriNetX enables researchers to apply a data-driven approach to
health research by providing web-based, on-demand access to
harmonized global electronic health record (EHR) and claims data
with a suite of highly intuitive analytics. TriNetX is utilized in
all parts of the drug development cycle, including protocol design
and feasibility, site selection and patient identification for
clinical trials, as well as serving clinical research for drugs
already in the market to help researchers understand efficacy,
risks and other market dynamics and to generate real-world evidence
(RWE) to support hypothesis and decision making, in real-time.
The longitudinal clinical and claims data representing over 400
million patients available through TriNetX is mapped to controlled
terminology and consists of clinical facts from hundreds of
healthcare organizations around the world, deep specialty data for
all therapeutic areas, including COVID-19, cardiovascular,
oncology, and rare disease, and linked medical claims, pharmacy
claims and EHR data.
"With a deep clinical focus and a highly scalable data strategy,
we believe TriNetX is well positioned for continued organic and
inorganic growth opportunities," said Joe
Bress, a Principal specializing in healthcare at The Carlyle
Group. "We're excited to partner with Gadi and the TriNetX
management team to help expand their global footprint and continue
investing in the company's mission to advance the collective
understanding of human health."
The investment in TriNetX is a continuation of Carlyle's
long-term global commitment to healthcare, in which it has invested
more than $15 billion of equity since
inception. Equity capital for the investment came from Carlyle
Partners VII, an $18.5 billion fund
that makes majority and strategic minority investments primarily in
the U.S. in targeted industries, including healthcare.
SVB Leerink served as exclusive financial advisor to
TriNetX.
About The Carlyle Group
The Carlyle Group (NASDAQ: CG) is a global investment firm with
deep industry expertise that deploys private capital across four
business segments: Corporate Private Equity, Real Assets, Global
Credit and Investment Solutions. With $221
billion of assets under management as of June 30, 2020, Carlyle's purpose is to invest
wisely and create value on behalf of its investors, portfolio
companies and the communities in which we live and invest. The
Carlyle Group employs more than 1,800 people in 31 offices across
six continents. Further information is available
at www.carlyle.com. Follow The Carlyle Group on Twitter
@OneCarlyle.
About TriNetX
TriNetX is the global health research
network that connects the world of drug discovery and development
from pharmaceutical company to study site, and investigator to
patient by sharing real-world data to make clinical and
observational research easier and more efficient. TriNetX combines
real time access to longitudinal clinical data with
state-of-the-art analytics to optimize protocol design and
feasibility, site selection, patient recruitment, and enable
discoveries through the generation of real-world evidence. The
TriNetX platform is HIPAA and GDPR compliant. For more
information, visit TriNetX at
http://www.trinetx.com or follow @TriNetX on Twitter.
Media Contacts:
Brittany Berliner
Brittany.Berliner@carlyle.com
+1 (212) 813 4839
Jennifer Haas
Jennifer.haas@trinetx.com
+ 1 (978) 697 3921
View original content to download
multimedia:http://www.prnewswire.com/news-releases/carlyle-makes-strategic-growth-investment-in-trinetx-acquires-majority-stake-in-leading-global-health-research-network-301134411.html
SOURCE TriNetX